Sotio

SOTIO
IndustryBiotechnology, Pharmaceutical
Founded2010
FounderPetr Kellner
Headquarters
Prague
,
Czech Republic
Key people
Radek Spisek, Ph.D., CEO
Revenue176,068,000 Czech koruna (2021) Edit this on Wikidata
−319,386,000 Czech koruna (2021) Edit this on Wikidata
−344,344,000 Czech koruna (2021) Edit this on Wikidata
Total assets6,689,850,000 Czech koruna (2021) Edit this on Wikidata
Number of employees
200
Websitehttps://www.sotio.com/

SOTIO Biotech[1] is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia.[2] The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.[3]

  1. ^ SOTIO, Biotech. "The Company". Sotio. Retrieved 2022-03-15.
  2. ^ "An In-Depth Look at Innovation on Cancer Research Day". BioSpace. Retrieved 2022-03-15.
  3. ^ "SOTIO's Quest To Build A Global Biopharma". bioprocessonline.com. Retrieved 2022-03-15.